专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010089287A1 WÄRMEÜBERTRAGER, INSBESONDERE HEIZKÖRPER FÜR KRAFTFAHRZEUGE 审中-公开
标题翻译：热交换器，尤其是加热器机动车
公开(公告)号：WO2010089287A1
公开(公告)日：2010-08-12
申请号：PCT/EP2010/051232
申请日：2010-02-02
申请人： BEHR GMBH & CO. KG , KOHL, Michael , FU, Ying
发明人： KOHL, Michael , FU, Ying
IPC分类号： F28D1/03 , F28F1/12 , F28F3/04 , F28D1/053
CPC分类号： F28F1/126 , F28D1/0391 , F28D1/05366 , F28F3/046 , F28F2001/027
摘要： Die Erfindung betrifft einen Wärmeübertrager, insbesondere Heizkörper (1) für Kraftfahrzeuge, umfassend einen Flachrohre (2) und Wellrippen (3) aufweisenden Block (4) sowie einen eintrittsseitigen und einen austrittsseitigen Sammelkasten (5, 6), wobei die Flachrohre flache Seiten mit eingeprägten Wirbelerzeugern aufweisen und von einem Kühlmittel durchströmbar sind. Es wird vorgeschlagen, dass die Flachrohre (2) eine lichte Weite (L) im Bereich von 0,9 bis 1,2 mm, vorzugsweise von 1,0 mm und die Wellrippen (3) eine Höhe (H) im Bereich von 6,3 bis 8,0 mm, vorzugsweise von 8,3 mm aufweisen.
摘要翻译：本发明涉及一种热交换器，特别是散热器（1），用于机动车辆，包括：扁平管（2）和波纹肋（3），其具有块（4）和入口侧和出口侧头部（5,6），其中所述扁平管平坦侧面与压花具有涡流发生器并通过由冷却剂流动。本发明提出，在扁平管（2）具有在0.9的范围内的净宽度（L）至1.2毫米，优选为1.0毫米，波纹状散热片（3）具有在6范围内的高度（H），，优选具有3至从8.3毫米8.0毫米。

2. 发明申请

WO2004050841A3 CASEIN KINASE I EPSILON AND CASEIN KINASE I DELTA AND SLEEP IN HUMANS 审中-公开
公开(公告)号：WO2004050841A3
公开(公告)日：2004-06-17
申请号：PCT/US2003/037992
申请日：2003-11-26
申请人： UNIVERSITY OF UTAH RESEARCH FOUNDATION , PTACEK, Louis , JONES, Christopher , FU, Ying-Hui
发明人： PTACEK, Louis , JONES, Christopher , FU, Ying-Hui
IPC分类号： C12N15/54 , C12N15/63 , C12N1/21 , C12N5/10 , C12N9/12
摘要： Genetic variants of the casein kinase I delta and casein kinase I epsilon genes are disclosed. Herein, two novel mutant casein kinase I delta genes and a novel mutant casein kinase I epsilon gene are disclosed. The protein products of the mutant casein kinase I delta gene and the mutant casein kinase I epsilon gene are also disclosed. The nucleic acid sequences of the invention lead to familial advanced sleep phase syndrome.

3. 发明申请

WO2004050841A2 CASEIN KINASE I EPSILON AND CASEIN KINASE I DELTA AND SLEEP IN HUMANS 审中-公开
公开(公告)号：WO2004050841A2
公开(公告)日：2004-06-17
申请号：PCT/US0337992
申请日：2003-11-26
申请人： UNIV UTAH RES FOUND , PTACEK LOUIS , JONES CHRISTOPHER , FU YING-HUI
发明人： PTACEK LOUIS , JONES CHRISTOPHER , FU YING-HUI
IPC分类号： C12N9/12 , C12N
CPC分类号： C12N9/1205
摘要： Genetic variants of the casein kinase I delta and casein kinase I epsilon genes are disclosed. Herein, two novel mutant casein kinase I delta genes and a novel mutant casein kinase I epsilon gene are disclosed. The protein products of the mutant casein kinase I delta gene and the mutant casein kinase I epsilon gene are also disclosed. The nucleic acid sequences of the invention lead to familial advanced sleep phase syndrome.
摘要翻译：公开了酪蛋白激酶Iδ和酪蛋白激酶Iε基因的遗传变体。本文中公开了两种新型突变酪蛋白激酶Iδ基因和新型突变酪蛋白激酶Iε基因。还公开了突变酪蛋白激酶Iδ基因和突变酪蛋白激酶Iε基因的蛋白质产物。本发明的核酸序列导致家族性晚期睡眠期综合征。

4. 发明申请

WO02086447A3 METHOD FOR ASSESSING RISK FOR CARDIAC DYSRHYTHMIA IN A HUMAN SUBJECT 审中-公开
标题翻译：用于评估人类受试者心脏硬膜血症风险的方法
公开(公告)号：WO02086447A3
公开(公告)日：2003-02-27
申请号：PCT/US0212652
申请日：2002-04-22
申请人： UNIV UTAH RES FOUND , PTACEK LOUIS , FU YING-HUI
发明人： PTACEK LOUIS , FU YING-HUI
IPC分类号： C12Q1/68 , C07H21/02 , C07H21/04 , C12P19/34
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The present invention relates to methods for assessing the risk of a patient for developing a potentially fatal cardiac dysrhythmia and for diagnosing Andersen's Syndrome. A tissue sample from a patient is obtained and the DNA or proteins of the sample isolated. From the DNA and protein isolates the sequence of the KCNJ2 gene or the Kir2.1 polypeptide can be obtained. The KCNJ2 gene or the Kir2.1 can be screened for alteration as compared to the wild-type sequence. An alteration in a copy of the KCNJ2 gene or a Kir2.1 polypeptide indicates that the patient has a high risk for developing a cardiac dysrhythmia and can be diagnosed with Andersen's Syndrome. The invention also relates to isolated nucleic acid molecules with one or more alterations as compared to the wild-type sequence.
摘要翻译：本发明涉及用于评估患者发展潜在致命性心脏心律失常并用于诊断安徒生综合征的风险的方法。获得来自患者的组织样品，并分离样品的DNA或蛋白质。从DNA和蛋白质分离物可以获得KCNJ2基因或Kir2.1多肽的序列。与野生型序列相比，KCNJ2基因或Kir2.1可以进行筛选。 KCNJ2基因或Kir2.1多肽拷贝的改变表明患者发生心脏性心律失常的风险很高，可以诊断为安徒生综合征。本发明还涉及与野生型序列相比具有一个或多个改变的分离的核酸分子。

5. 发明申请

WO2002086447A2 METHOD FOR ASSESSING RISK FOR CARDIAC DYSRHYTHMIA IN A HUMAN SUBJECT 审中-公开
标题翻译：用于评估人类受试者心脏硬膜血症风险的方法
公开(公告)号：WO2002086447A2
公开(公告)日：2002-10-31
申请号：PCT/US2002/012652
申请日：2002-04-22
申请人： UNIVERSITY OF UTAH RESEARCH FOUNDATION , PTACEK, Louis , FU, Ying-Hui
发明人： PTACEK, Louis , FU, Ying-Hui
IPC分类号： G01N
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The present invention relates to methods for assessing the risk of a patient for developing a potentially fatal cardiac dysrhythmia and for diagnosing Andersen's Syndrome. A tissue sample from a patient is obtained and the DNA or proteins of the sample isolated. From the DNA and protein isolates the sequence of the KCNJ2 gene or the Kir2.1 polypeptide can be obtained. The KCNJ2 gene or the Kir2.1 can be screened for alteration as compared to the wild-type sequence. An alteration in a copy of the KCNJ2 gene or a Kir2.1 polypeptide indicates that the patient has a high risk for developing a cardiac dysrhythmia and can be diagnosed with Andersen's Syndrome. The invention also relates to isolated nucleic acid molecules with one or more alterations as compared to the wild-type sequence.
摘要翻译：本发明涉及用于评估患者发展潜在致命性心脏心律失常并用于诊断安徒生综合征的风险的方法。获得来自患者的组织样品，并分离样品的DNA或蛋白质。从DNA和蛋白质分离物可以获得KCNJ2基因或Kir2.1多肽的序列。与野生型序列相比，KCNJ2基因或Kir2.1可以进行筛选。 KCNJ2基因或Kir2.1多肽拷贝的改变表明患者发生心脏性心律失常的风险很高，可以诊断为安徒生综合征。本发明还涉及与野生型序列相比具有一个或多个改变的分离的核酸分子。

6. 发明申请

WO2011131925A3 OSMIUM (II) ARENE AZO ANTI-CANCER COMPLEXES 审中-公开
标题翻译： OSMIUM（II）ARENE AZO抗癌复合物
公开(公告)号：WO2011131925A3
公开(公告)日：2012-03-29
申请号：PCT/GB2011000591
申请日：2011-04-15
申请人： UNIV WARWICK , FU YING , SADLER PETER JOHN , HABTEMARIAM ABRAHA
发明人： FU YING , SADLER PETER JOHN , HABTEMARIAM ABRAHA
IPC分类号： C07F15/00 , A61K31/00 , A61P35/00 , C07F17/02
CPC分类号： C07F15/002
摘要： The present invention relates to the use of certain osmium containing complexes such as cytotoxic agents particularly for the treatment of cancer. There is also provided novel osmium containing complexes, as well as pharmaceutical formulations comprising such complexes.
摘要翻译：本发明涉及某些含锇复合物如细胞毒剂特别用于治疗癌症的用途。还提供了新颖的含锇络合物，以及包含这种复合物的药物制剂。

7. 发明申请

WO2006020959A2 SUBSTITUTED BENZOFUSED HETEROCYCLES 审中-公开
标题翻译：取代的苯并呋喃酮
公开(公告)号：WO2006020959A2
公开(公告)日：2006-02-23
申请号：PCT/US2005/028935
申请日：2005-08-12
申请人： AMGEN INC. , CHEN, Xi , CHEN, Xiaoqi , CONNORS, Richard, Victor , DAI, Kang , FU, Ying , JAEN, Juan, C. , KIM, Yong-Jae , LI, Leping , LIZARZABURU, Michael, E. , MIHALIC, Jeffrey, T. , SHUTTLEWORTH, Stephen, J.
发明人： CHEN, Xi , CHEN, Xiaoqi , CONNORS, Richard, Victor , DAI, Kang , FU, Ying , JAEN, Juan, C. , KIM, Yong-Jae , LI, Leping , LIZARZABURU, Michael, E. , MIHALIC, Jeffrey, T. , SHUTTLEWORTH, Stephen, J.
CPC分类号： C07D417/06 , C07D217/24 , C07D223/16 , C07D243/14 , C07D401/06 , C07D401/12 , C07D487/04 , C07D491/10
摘要： The present invention relates to the compounds of Formula (I), their preparation and pharmaceutical compositions comprising them. The compounds and pharmaceutical compositions are useful, for example, for the treatment and prevention of obesity, obesity-related disorders and eating disorders.
摘要翻译：本发明涉及式（I）的化合物，其制备方法和包含它们的药物组合物。化合物和药物组合物可用于例如治疗和预防肥胖，肥胖相关疾病和进食障碍。

8. 发明申请

WO02055667A3 IDENTIFICATION OF AN ADVANCED SLEEP PHASE SYNDROME GENE IN HUMANS 审中-公开
标题翻译：在人体中鉴定出先进的睡眠相关基因
公开(公告)号：WO02055667A3
公开(公告)日：2003-04-17
申请号：PCT/US0200741
申请日：2002-01-11
申请人： UNIV UTAH RES FOUND , PTACEK LOUIS , FU YING-HUI , JONES CHRISTOPHER , VIRSHUP DAVID
发明人： PTACEK LOUIS , FU YING-HUI , JONES CHRISTOPHER , VIRSHUP DAVID
IPC分类号： C07K14/47 , C12N9/12 , C12N9/16 , G01N33/68 , C07H21/04 , C12P19/34
CPC分类号： C12N9/16 , C07K14/4702 , C12N9/12
摘要： The present invention includes the disclosure of the hPER2 gene and a mutant of the hPER2 gene that participates in the human circadian biological clock. The product of the mutant hPER2 gene found in some familial advanced sleep phase syndrome patients is hypophosphorylated by casein kinase epsilon due to the serine-to-glycine mutation caused by the point mutation of the genomic sequence. Specifically, this serine-to-glycine mutation affects the casein kinase epsilon binding region of the hPER2 protein, thus blocking the phosphorylation cascade ordinarily caused by the binding of casein kinase epsilon to hPER2.
摘要翻译：本发明包括参与人类昼夜节律生物钟的hPER2基因和hPER2基因的突变体的公开。在一些家族性晚期睡眠综合征患者中发现的突变型hPER2基因的产物由于由基因组序列的点突变引起的丝氨酸至甘氨酸突变而被酪蛋白激酶ε磷酸化。具体来说，该丝氨酸 - 甘氨酸突变影响hPER2蛋白质的酪蛋白激酶ε结合区域，从而阻止通常由酪蛋白激酶ε结合到hPER2引起的磷酸化级联。

9. 发明申请

WO2011131925A2 OSMIUM (II) ARENE AZO ANTI-CANCER COMPLEXES 审中-公开
标题翻译： OSMIUM（II）ARENE AZO抗癌复合物
公开(公告)号：WO2011131925A2
公开(公告)日：2011-10-27
申请号：PCT/GB2011/000591
申请日：2011-04-15
申请人： UNIVERSITY OF WARWICK , FU, Ying , SADLER, Peter, John , HABTEMARIAM, Abraha
发明人： FU, Ying , SADLER, Peter, John , HABTEMARIAM, Abraha
IPC分类号： C07F15/00 , C07F17/02 , A61P35/00 , A61K31/00
CPC分类号： C07F15/002
摘要： The present invention relates to the use of certain osmium containing complexes such as cytotoxic agents particularly for the treatment of cancer. There is also provided novel osmium containing complexes, as well as pharmaceutical formulations comprising such complexes.
摘要翻译：本发明涉及某些含锇复合物如细胞毒剂特别用于治疗癌症的用途。还提供了新颖的含锇络合物，以及包含这种复合物的药物制剂。

10. 发明申请

WO2006020959A3 SUBSTITUTED BENZOFUSED HETEROCYCLES 审中-公开
标题翻译：取代的苯并呋喃酮
公开(公告)号：WO2006020959A3
公开(公告)日：2007-01-11
申请号：PCT/US2005028935
申请日：2005-08-12
申请人： AMGEN INC , CHEN XI , CHEN XIAOQI , CONNORS RICHARD VICTOR , DAI KANG , FU YING , JAEN JUAN C , KIM YONG-JAE , LI LEPING , LIZARZABURU MICHAEL E , MIHALIC JEFFREY T , SHUTTLEWORTH STEPHEN J
发明人： CHEN XI , CHEN XIAOQI , CONNORS RICHARD VICTOR , DAI KANG , FU YING , JAEN JUAN C , KIM YONG-JAE , LI LEPING , LIZARZABURU MICHAEL E , MIHALIC JEFFREY T , SHUTTLEWORTH STEPHEN J
IPC分类号： C07D217/24 , C07D223/16 , C07D243/14 , C07D401/06 , C07D401/12 , C07D417/06 , C07D487/04 , C07D491/10
CPC分类号： C07D417/06 , C07D217/24 , C07D223/16 , C07D243/14 , C07D401/06 , C07D401/12 , C07D487/04 , C07D491/10
摘要： The present invention relates to the compounds of Formula (I), their preparation and pharmaceutical compositions comprising them. The compounds and pharmaceutical compositions are useful, for example, for the treatment and prevention of obesity, obesity-related disorders and eating disorders.
摘要翻译：本发明涉及式（I）的化合物，其制备方法和包含它们的药物组合物。化合物和药物组合物可用于例如治疗和预防肥胖，肥胖相关疾病和进食障碍。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式